• Explore /
  • Poster
  • / Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.

Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.

Abstract Poster

Authors

Yoshiaki Nakamura

Yoshiaki Nakamura

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

Yoshiaki Nakamura , Taito Esaki , Tomohiro Nishina , Yoshito Komatsu , Satoshi Yuki , Eiji Shinozaki , Hiroya Taniguchi , Takeshi Kato , Ken Kato , Shogo Nomura , Takashi Ikeno , Yukiko Ishiguro , Koji Takahashi , Tsukiko Higuchi , Akihiro Sato , Justin Iver Odegaard , Takeshi Kuwata , Kouji Matsushima , Tetsuya Nakatsura , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000033182

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 98)

DOI

10.1200/JCO.2024.42.3_suppl.98

Abstract #

98

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Yoshiaki Nakamura

First Author: Jordan Kardos

First Author: Michael Masetti

First Author: Tae-Yong Kim